Randomized Clinical Trial for the Prevention of Cognitive Impairment in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin

Trial Profile

Randomized Clinical Trial for the Prevention of Cognitive Impairment in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Warfarin
  • Indications Embolism and thrombosis; Stroke
  • Focus Pharmacodynamics
  • Acronyms GIRAF
  • Most Recent Events

    • 24 Oct 2017 Planned End Date changed from 1 May 2018 to 1 Oct 2018.
    • 24 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top